Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial

Jens Christian Laursen; Viktor Rotbain Curovic; Marjolein Y.A.M. Kroonen; Niels Jongs; Emilie H. Zobel; Tine W. Hansen; Marie Frimodt-Møller; Gozewijn D. Laverman; Adriaan Kooy; Frederik Persson; Hiddo J.L. Heerspink; Christian Stevns Hansen; Peter Rossing

doi:10.1111/dom.15180

Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial

Jens Christian Laursen^*, Viktor Rotbain Curovic, Marjolein Y.A.M. Kroonen, Niels Jongs, Emilie H. Zobel, Tine W. Hansen, Marie Frimodt-Møller, Gozewijn D. Laverman, Adriaan Kooy, Frederik Persson, Hiddo J.L. Heerspink, Christian Stevns Hansen, Peter Rossing

^*Corresponding author for this work

Groningen Kidney Center (GKC)

Research output: Contribution to journal › Letter › Academic › peer-review

2 Citations (Scopus)

208 Downloads (Pure)

Original language	English
Pages (from-to)	3064-3067
Number of pages	4
Journal	Diabetes, Obesity and Metabolism
Volume	25
Issue number	10
DOIs	https://doi.org/10.1111/dom.15180
Publication status	Published - Oct-2023

Keywords

clinical trial
diabetes complications
diabetic neuropathy
empagliflozin
linagliptin
SGLT2 inhibitor

Access to Document

10.1111/dom.15180

Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetesFinal publisher's version, 608 KBLicence: Taverne

Handle.net

Persistent link

Cite this

Laursen, J. C., Rotbain Curovic, V., Kroonen, M. Y. A. M., Jongs, N., Zobel, E. H., Hansen, T. W., Frimodt-Møller, M., Laverman, G. D., Kooy, A., Persson, F., Heerspink, H. J. L., Hansen, C. S., & Rossing, P. (2023). Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial. Diabetes, Obesity and Metabolism, 25(10), 3064-3067. https://doi.org/10.1111/dom.15180

@article{9bfac1b7403c4fa99f0fbb540c8ea17a,

title = "Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial",

keywords = "clinical trial, diabetes complications, diabetic neuropathy, empagliflozin, linagliptin, SGLT2 inhibitor",

author = "Laursen, {Jens Christian} and {Rotbain Curovic}, Viktor and Kroonen, {Marjolein Y.A.M.} and Niels Jongs and Zobel, {Emilie H.} and Hansen, {Tine W.} and Marie Frimodt-M{\o}ller and Laverman, {Gozewijn D.} and Adriaan Kooy and Frederik Persson and Heerspink, {Hiddo J.L.} and Hansen, {Christian Stevns} and Peter Rossing",

year = "2023",

month = oct,

doi = "10.1111/dom.15180",

language = "English",

volume = "25",

pages = "3064--3067",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley",

number = "10",

}

Laursen, JC, Rotbain Curovic, V, Kroonen, MYAM, Jongs, N, Zobel, EH, Hansen, TW, Frimodt-Møller, M, Laverman, GD, Kooy, A, Persson, F, Heerspink, HJL, Hansen, CS & Rossing, P 2023, 'Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial', Diabetes, Obesity and Metabolism, vol. 25, no. 10, pp. 3064-3067. https://doi.org/10.1111/dom.15180

Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial. / Laursen, Jens Christian; Rotbain Curovic, Viktor; Kroonen, Marjolein Y.A.M. et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 10, 10.2023, p. 3064-3067.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes

T2 - An exploratory, randomized, open-label, crossover trial

AU - Laursen, Jens Christian

AU - Rotbain Curovic, Viktor

AU - Kroonen, Marjolein Y.A.M.

AU - Jongs, Niels

AU - Zobel, Emilie H.

AU - Hansen, Tine W.

AU - Frimodt-Møller, Marie

AU - Laverman, Gozewijn D.

AU - Kooy, Adriaan

AU - Persson, Frederik

AU - Heerspink, Hiddo J.L.

AU - Hansen, Christian Stevns

AU - Rossing, Peter

PY - 2023/10

Y1 - 2023/10

KW - clinical trial

KW - diabetes complications

KW - diabetic neuropathy

KW - empagliflozin

KW - linagliptin

KW - SGLT2 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85164196800&partnerID=8YFLogxK

U2 - 10.1111/dom.15180

DO - 10.1111/dom.15180

M3 - Letter

C2 - 37385968

AN - SCOPUS:85164196800

SN - 1462-8902

VL - 25

SP - 3064

EP - 3067

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 10

ER -

Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial

Keywords

Access to Document

Handle.net

Other files and links

Cite this